Dana-Farber’s Breast Oncology Center shared a post on X:
“Here’s the most recent Breast Cancer Research Digest – a summary of last week’s publications from select high-impact journals (December 16th-20th, 2024).”
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
Authors: Kalinsky K, et al.
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Authors: Lakhani NJ, et al.
Trastuzumab Deruxtecan with Nivolumab in HER2- Expressing Metastatic Breast or Urothelial Cancer: Analysis of the Phase Ib DS8201-A-U105 Study.
Authors: Hamilton E, et al.
Magnetic Sentinel Lymph Node Biopsy in Early Breast Cancer Patients: An Individual Patient Data Meta-analysis of Tracer Uptake.
Authors: Christenhusz A, et al.
A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.
Authors: Caruso JA, et al.
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.
Authors: Cucciniello L, et al.
Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real- world study.
Authors: Bae SJ, et al.
Intraoperative radiotherapy versus whole breast radiotherapy in early-stage breast cancer: a retrospective outcome analysis based on ASTRO guidelines on PBI.
Authors: SY, et al.
Protective effects of miR-24-2-5p in early stages of breast cancer bone metastasis.
Authors: Puppo M, et al.
Association Between Delayed/Forgone Medical Care and Resource Utilization Among Women with Breast Cancer in the United States.
Authors: Reddy KP, et al.
Oncogene activated human breast luminal progenitors contribute basally located myoepithelial cells.
Authors: Kohler KT, et al.
miR-484 as an “OncomiR” in Breast Cancer Promotes Tumorigenesis by Suppressing Apoptosis Genes.
Authors: Tahtasakal R, et al.
ERBB2/HOXB13 co-amplification with interstitial loss of BRCA1 defines a unique subset of breast cancers.
Authors: Mitsiades IR, et al.
The EstroGene2.0 database for endocrine therapy response and resistance in breast cancer.
Authors: Li Z, et al.
Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness.
Authors: Chang KC, et al.
Incidence of patient-reported fatigue developing on palbociclib and endocrine therapy for advanced HR+ HER2- breast cancer.
Authors: Rahman SA, et al.
A Randomized Controlled Feasibility Study to Evaluate the Online Delivery of Storytelling Through Music With Oncology Nurses.
Authors: Phillips CS, et al.
